Novocure Stock Price, News & Analysis

Novocure (NASDAQ: NVCR) has scheduled its second quarter 2025 financial results announcement for July 24, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss its financial performance for the three and six-month periods ending June 30, 2025.

The presentation materials will be accessible through Novocure's investor relations website and will remain available for at least 14 days after the call. The company uses its investor relations website to disclose material non-public information in compliance with Regulation FD.

Zai Lab and Novocure announced positive Phase 3 PANOVA-3 trial results for Tumor Treating Fields (TTFields) therapy in pancreatic cancer treatment. The trial, combining TTFields with gemcitabine and nab-paclitaxel, demonstrated significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. The study showed median overall survival of 16.2 months versus 14.2 months in the control group (HR 0.82; p=0.039). Notable improvements included one-year survival rate (68.1% vs 60.2%) and pain-free survival (15.2 vs 9.1 months). The therapy was well-tolerated with only mild to moderate skin adverse events. Novocure plans to submit data to FDA in second half of 2025 for premarket approval. The results will be presented at the 2025 ASCO Annual Meeting and published in the Journal of Clinical Oncology.

Novocure (NVCR) announced positive Phase 3 PANOVA-3 trial results for its Tumor Treating Fields (TTFields) therapy in pancreatic cancer, showing significant improvement in overall survival. When combined with gemcitabine and nab-paclitaxel, TTFields therapy demonstrated a median overall survival of 16.2 months versus 14.2 months in the control group (HR 0.82; p=0.039). The therapy showed notable improvements in one-year survival rates (68.1% vs 60.2%) and pain-free survival (15.2 vs 9.1 months). Quality of life metrics also improved significantly, with better outcomes in global health status, pain management, and digestive problems. The treatment was well-tolerated with only mild to moderate skin adverse events. Novocure plans to submit these results to the FDA in H2 2025 for premarket approval, with additional submissions planned for EU, Japan, and other markets.

Novocure (NVCR) has announced two upcoming investor events. The company will host a PANOVA-3 Investor Event on May 31, 2025, at 8:00 p.m. ET in Chicago to discuss data from their successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Dr. Vincent Picozzi, a medical oncologist and trial investigator, will join the leadership team to review results.

Additionally, CEO Ashley Cordova will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 p.m. ET. CFO Christoph Brackmann will join for one-on-one investor meetings. Both events will be webcast and available for replay on Novocure's website.

Novocure (NVCR) reported Q1 2025 financial results with net revenues of $155.0 million, up 12% year-over-year. The company achieved 4,268 active patients on Tumor Treating Fields therapy globally as of March 31, 2025.

Key financial metrics include: 75% gross margin, net loss of $34.3 million ($0.31 per share), and cash position of $929.1 million. Regional revenue contributions: US ($93.2M), Germany ($18.7M), France ($17.9M), and Japan ($8.7M).

Notable developments include CE Mark approval for Optune Lua for metastatic NSCLC treatment and upcoming presentation of Phase 3 PANOVA-3 pancreatic cancer trial results at ASCO 2025. The company faces potential tariff impacts of up to $8-11 million in 2025 depending on policy implementation.

Novocure (NASDAQ: NVCR) has received CE Mark approval for Optune Lua® to treat metastatic non-small cell lung cancer (NSCLC) in combination with immune checkpoint inhibitors or docetaxel after platinum-based treatment progression.

The approval is based on the Phase 3 LUNAR trial results, which showed a significant 3.3-month median overall survival extension (13.2 vs 9.9 months, P=0.035). Notably, patients receiving Optune Lua with immune checkpoint inhibitors showed a 7.7-month survival benefit (18.5 vs 10.8 months, P=0.03).

Optune Lua, a wearable device delivering Tumor Treating Fields (TTFields), demonstrated manageable safety with mainly low-grade skin-related events (65.4% of patients). Only 5% experienced Grade 3 events, with no Grade 4 or 5 toxicities reported.

Novocure (NASDAQ: NVCR) has announced it will release its first quarter 2025 financial results on April 24, 2025, before U.S. markets open. The company's management will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss the financial performance for the quarter ending March 31, 2025.

The presentation slides and webcast will be accessible through Novocure's investor relations website and will remain available for a minimum of 14 days after the call.

Novocure (NASDAQ: NVCR) has announced its participation in the upcoming Leerink Global Healthcare Conference scheduled for March 11, 2025. The company's Chief Financial Officer, Christoph Brackmann, will engage in a fireside chat at 4:20 p.m. EST and conduct one-on-one meetings with investors throughout the conference.

Interested parties can access a live audio webcast of the presentation through Novocure's Investor Relations webpage. The recording will remain available for replay for a minimum of 14 days after the event.

Novocure (NVCR) reported strong financial results for Q4 and full year 2024, with total net revenues reaching $605.2 million for the year, up 19% year-over-year. Q4 revenues were $161.3 million, showing a 21% increase.

Key developments include FDA approval of Optune Lua for metastatic non-small cell lung cancer treatment and positive Phase 3 PANOVA-3 trial results for pancreatic cancer. The company maintained 4,126 active patients globally, with 4,077 using Optune Gio for glioblastoma treatment.

Regional Q4 revenues: US ($107.2M), Germany ($17.4M), France ($15.7M), and Japan ($8.5M). Gross margin was 79%. The company reported a quarterly net loss of $65.9 million ($0.61 per share) with adjusted EBITDA of $2.6 million.